La catena delle opzioni mostra i dati chiave delle opzioni azionarie di VS Media Holdings a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per VS Media Holdings..

VS Media Holdings (NASDAQ:VSME) Azioni, Catena delle Opzioni

VS Media Holdings

VS Media Holdings Ltd manages a global network of digital Creators who create and publish content to social media platforms such as YouTube, Facebook, Instagram, and TikTok. Its Creators include influencers, KOLs-Key Opinion Leaders, bloggers, and other content creators who cultivate fanbases on social media platforms. The company's business provides value to two major business stakeholders: Creators and Brands. Its Value to Creators: It empowers and supports Creators by providing them with production facilities, training, and funding to produce quality content. Its Value to Brands: the company bridges the divide between Brands and Creators by helping Brands reach their target audience effectively by advising on content strategy and budget and recommending specific Creators.

VS Media Holdings Limited - Class A Ordinary Shares

VS Media Holdings Ltd

Trading Ideas

FATN

FatPipe Shares Halted On Circuit Breaker To The Upside

Truist Securities analyst Jamie Cook maintains Oshkosh (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OSK#NYSE">OSK</a>) with a Hold and lowers the price target from $118 to $94.

News

Price Target

Analyst Ratings

Truist Securities Maintains Hold on Oshkosh, Lowers Price Target to $94

IPOs

FatPipe IPO Opens For Trade At $6.50/Share; IPO Priced At $5.75/Share

Pacira BioSciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) on Monday settled its litigations with Fresenius Kabi USA, Jiangsu Hengrui Pharmaceuticals Co., Ltd., and eVenus Pharmaceuticals Laboratories, Inc. related to patents for Exparel (bupivacaine <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">liposome injectable suspension)</a>.
Exparel is Pacira BioSciences' non-opioid analgesic pain management and is indicated for postsurgical analgesia.
As part of the settlement, the parties will file Consent Judgments with the United States Court of Appeals for the Federal Circuit and the United States District Courts for the District of New Jersey and the Northern District of Illinois that enjoin Fresenius from marketing generic bupivacaine liposome injectable suspension before the expiration of the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g44674361/pacira-biosciences-announces-settlement-of-u-s-patent-litigation-for-exparel" rel="noreferrer noopener">patents-in-suit</a>.
In settlement of all outstanding claims in the litigations, Pacira has agreed to provide Fresenius with a license to Pacira&#8217;s patents required to manufacture and sell certain volume-limited amounts of generic bupivacaine liposome injectable suspension in the U.S. beginning on a confidential date that is sometime in early 2030.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/01/42854744/pacira-biosciences-secures-fda-approval-for-new-iovera-smarttip-to-manage-chronic-low-back-pain" rel="noreferrer noopener">Pacira BioSciences Secures FDA Approval For New iovera SmartTip to Manage Chronic Low Back Pain</a>
The license will permit generic bupivacaine liposome injectable suspension entry before the July 2, 2044, expiration date of the last-to-expire of Pacira&#8217;s Orange Book-listed patents for Exparel.
While the agreed-upon volume-limited percentages are confidential, they begin at a high-single-digit percentage of the total volumes distributed in the U.S. market and increase gradually in each 12-month period following the volume-limited entry date until reaching a percentage in the low thirties in 2033 and increasing modestly in each of the next two 12-month periods before reaching a maximum percentage in the high thirties of the total volumes distributed in the U.S. for the final three years of the agreement.
In addition, Pacira has agreed to provide Fresenius with a license to Pacira&#8217;s patents required to manufacture and sell an unlimited quantity of generic bupivacaine liposome injectable suspension in the U.S. beginning no earlier than 2039.
In an SEC <a href="https://www.benzinga.com/secfilings/25/04/44674982/pacira-biosciences-inc-general-corporate-statement-form8" target="_blank" rel="noreferrer noopener">filing</a>, the company&#8217;s expected savings concerning, among other things, the avoidance of the fees, costs, time and resources associated with continuing the Litigations, the company will pay the Fresenius Parties $7.0 million.
Exparel net product sales were $147.7 million in the fourth quarter of 2024, a 3% <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g44024616/pacira-biosciences-reports-fourth-quarter-and-full-year-2024-financial-results" rel="noreferrer noopener">year over year increase</a>.
In August 2024, Pacira BioSciences announced that the U.S. District Court for the District of New Jersey found that the company's U.S. Patent No. 11,033,495 (the ‘495 patent)&nbsp;<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40321378/pain-management-focused-pacira-biosciences-loses-patent-fight-for-key-drug-jp-morga" rel="noreferrer noopener">is not valid</a>.
In November 2021, Pacira BioSciences&nbsp;<a target="_blank" href="https://investor.pacira.com/news-releases/news-release-details/pacira-files-lawsuit-against-evenus-patent-infringement?tblci=GiCUX7wvU_AgmIIiQduNYr6JQuJQLy6SZJGvpyeZuCzyqiCN1VcoxvTN4f7-y-PqATDviEo" rel="noreferrer noopener">filed</a>&nbsp;a lawsuit in the United States District Court for the District of New Jersey against&nbsp;eVenus Pharmaceutical Laboratories for patent infringement of U.S. Patent Number 11,033,495.
Analyst Reaction:
<ul>
<li>HC Wainwright maintains Pacira BioSciences with a Buy, raising the price target <a href="https://www.benzinga.com/quote/PCRX/analyst-ratings" target="_blank" rel="noreferrer noopener">from $48 to $65</a>.</li>
<li>Needham reiterates Pacira BioSciences with a Buy and maintains a price target of $32.</li>
</ul>
Price Action: PCRX stock is up 16.8% at $26.77 at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/25/04/44685591/walgreens-boots-alliance-q2-earnings-beats-expectations-suspends-guidance-amid-pending-private-equity-deal-with-sycamore-partners" target="_blank" rel="noreferrer noopener">Walgreens Boots Alliance Q2 Profit Falls 47.5%, Suspends Guidance On Pending Private Equity Deal</a></li>
</ul>
Photo: Shutterstock

Biotech

Health Care

Legal

Movers

General

PCRX

Pacira Settles Patent Dispute Over Exparel With Fresenius, Delays Pain Med' Generics Entry Until 2030, Stock Jumps

Mark Cuban doesn't throw around financial panic lightly—but over the weekend, the billionaire entrepreneur and <a href="https://www.benzinga.com/personal-finance/25/02/43435413/mark-cubans-cost-plus-marketplace-now-sells-over-6000-medicines-saving-customers-between-40-60-by-cutting-out-the-middle-man">Cost Plus Drugs co-founder</a> lit up Bluesky with a warning that's hard to ignore.&nbsp;
In his view, the latest combination of sweeping tariffs and deep government cuts could send the U.S. economy spiraling into a crisis even worse than 2008.
"If the new tariffs stay in place for multiple years, and are enforced and inflationary, and DOGE continues to cut and fire, we will be in a far worse situation than 2008," <a href="https://bsky.app/profile/mcuban.bsky.social/post/3lm3z4inx6c2b">Cuban posted on Saturday</a>, responding to a user who asked him about the "worst case" economic impact of Trump's tariff plan.
Don't Miss:
<ul>
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.55 per share now</a>.</li>
<li>How do billionaires pay less in income tax than you?<a href="https://www.benzinga.com/money/tax-deferring-adv"> Tax deferring is their number one strategy</a>.</li>
</ul>
For those who forgot—or maybe just blocked it out—2008 wasn't just a bad year. It was the year the financial system cracked. Banks collapsed. Millions lost homes, jobs, and retirement savings. The stock market tanked, credit dried up, and the government had to step in with massive bailouts just to keep the economy breathing. It was the worst financial crisis since the Great Depression.
And Cuban's not being dramatic—he's drawing direct parallels.
This <a href="https://www.benzinga.com/markets/equities/25/04/44642355/trumps-25-auto-tariffs-spark-stellantis-layoffs-gm-expansion-uaws-shawn-fain-calls-job-cuts-completely-unnecessary">latest round of tariffs</a>, announced by the Trump administration last Wednesday, marks a sharp escalation in trade restrictions. They're aimed at foreign imports but could hit American consumers in the wallet, fast. Add to that the Domestic Office of Government Efficiency pushing aggressive federal workforce reductions, and Cuban sees a dangerous storm forming.
Trending: <a href="https://www.benzinga.com/money/arrived-private-credit-fund">Bezos' Favorite Real Estate Platform Launches A Way To Ride The Ongoing Private Credit Boom</a>
Though he didn't go into detail on DOGE's connection to the economy, there's already been fallout. Among the targeted agencies? The Consumer Financial Protection Bureau and the IRS's tax evasion enforcement arm—two departments that help regulate bad behavior and secure government revenue. Cutting those could mean less consumer protection and more unpaid taxes.
Cuban did offer a <a href="https://bsky.app/profile/mcuban.bsky.social/post/3lm4meuumzc2n">glimpse at a "best case" scenario</a> when asked what could cool things off:
"Best case he turns off Apr 2nd tariffs Monday. Leaves the 10pct tariffs (not great, but realistic). <a href="https://www.benzinga.com/news/25/03/44575557/mark-cuban-says-if-they-replaced-elon-musk-with-him-hes-still-try-to-make-government-smaller-by-cutting-a-lot-of-people">Elon leaves Doge</a>, which decides to stagger the cuts over 3 yrs, accounting for local impact. That slows the economy, reducing interest rates, reducing payments on debt to affordable levels."
In other words, scale it back. Or at least, don't yank the rug all at once.
But Cuban's bottom line is clear: this isn't just about political strategy—it's about economic survival.
And if his predictions are right, the price of inaction might be a lot more than higher grocery bills.
Read Next:
<ul>
<li>BlackRock is calling 2025 the year of alternative assets. <a href="https://www.benzinga.com/money/masterworks">One firm from NYC has quietly built a group of 60,000+ investors who have all joined in on an alt asset class previously exclusive to billionaires like Bezos and Gates.</a></li>
<li>Have $200K saved?<a href="https://www.benzinga.com/money/have-200k-saved-heres-how-to-turn-it-into-lasting-wealth"> Here's how to turn it into lasting wealth</a></li>
</ul>

Personal Finance

Mark Cuban Says Brace For A 'Far Worse Than 2008' Financial Crisis If The New Tariffs Stick Around and DOGE Continues Cutting and Firing

Truist Securities analyst Jamie Cook maintains AGCO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGCO#NYSE">AGCO</a>) with a Buy and lowers the price target from $125 to $105.

AGCO

Truist Securities Maintains Buy on AGCO, Lowers Price Target to $105

WIIM

Wells Fargo shares are trading higher after Piper Sandler upgraded the stock from Neutral to Overweight and announced a price target of $77.

Truist Securities analyst Jamie Cook maintains CNH Industrial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNH#NYSE">CNH</a>) with a Buy and lowers the price target from $17 to $16.

Truist Securities Maintains Buy on CNH Industrial, Lowers Price Target to $16

RPM International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RPM#NYSE">RPM</a>) shares are trading lower after the <a href="https://www.benzinga.com/pressreleases/25/04/b44680994/rpm-reports-fiscal-2025-third-quarter-results" target="_blank" rel="noreferrer noopener">company reported fiscal third-quarter results</a>.
Sales declined 3% year over year to $1.48 billion, missing the consensus of $1.51 billion.
Sales decreased due to weak demand from specialty OEM manufacturing end markets and unfavorable weather conditions.
Geographically, sales decreased in North America, while Latin America and Asia / Pacific&nbsp;declined.
Adjusted EPS was&nbsp;$0.35,&nbsp;<a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">missing the consensus of&nbsp;$0.49.</a>
Adjusted EBIT fell 29% to $78.2 million due to reduced production volumes, adverse foreign currency impacts, and temporary costs related to MAP 2025 plant consolidations and start-up activities.
For the nine months ended Feb. 28, operating cash flow was $619.0 million, supported by MAP 2025-driven efficiency.
Total debt decreased to&nbsp;$2.10 billion&nbsp;from&nbsp;$2.19 billion, driven by the reduction of $0.09 billion on improved cash flow to repay higher-cost debt.
Capital expenditures rose to&nbsp;$158.9&nbsp;million from $138.1&nbsp;million a year ago, driven by investments in shared RPM centers, a new production facility in India, and MAP 2025-enabled plant consolidations.
The company returned&nbsp;$242.6&nbsp;million&nbsp;to stockholders via dividends and buybacks.
Frank C. Sullivan, RPM chairman and CEO said, &#8221;Unseasonably cold weather in the southern U.S. and wildfires in the west reduced demand in geographies that typically have more construction and outdoor project activity in winter months.&#8221;
&#8220;As we look toward the fourth quarter, macroeconomic conditions are challenging, but we are seeing pockets of positive momentum and are leveraging our focus on repair and maintenance in both construction and consumer end markets. As demonstrated in prior economic cycles, the ability of our products and services to extend asset life becomes even more attractive to end users when budgets are tight.&#8221;
&#8221;Additionally, RPM associates continue to implement initiatives to outgrow our markets, including new product introductions, and achieve efficiency improvements. We anticipate that this will result in modest earnings growth in the fourth quarter with the financial benefits of MAP 2025 becoming even more evident when sustained volume growth returns.&#8221;
&#8220;While the tariff situation is dynamic, most of our businesses have limited cross-border trade for raw material procurement and finished good sales. This helps mitigate the effects of tariffs; however, we are not immune, and we assume that raw material inflation will increase from low-single-digits to mid-single digits as a result of currently known tariffs,&#8221;
Outlook:&nbsp;For the&nbsp;fourth quarter, RPM&nbsp;expects consolidated sales to remain flat <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">compared to prior-year records</a>.
In particular, CPG sales is expected to remain flat Y/Y, PCG sales to increase in the mid-single-digit percentage range and SPG and Consumer Group sales to decline in the low-single-digit percentage range.
In the quarter, the company expects adjusted EBIT to be up in the low-single-digit percentage range Y/Y.
Investors can gain exposure to the stock via&nbsp;Invesco Dorsey Wright Basic Materials Momentum ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYZ#NASDAQ">PYZ</a>) and Invesco S&amp;P MidCap Quality ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XMHQ#NYSE">XMHQ</a>).
Price Action: RPM shares are down 4.38% at $102.02 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/04/44679853/wall-street-eyes-recovery-as-sp-500-nasdaq-futures-rise-after-trumps-tariff-driven-selloff-wipes-out-9-trillion-in-six-weeks" target="_blank" rel="noreferrer noopener">Wall Street Eyes Recovery As S&amp;P 500, Nasdaq Futures Rise After Trump&#8217;s Tariff-Driven Selloff Wipes Out $9 Trillion In Six Weeks</a></li>
</ul>
Photo: Shutterstock/PJ McDonnell

Earnings

Equities

Large Cap

Guidance

PowerShares Dynamic Basic Materials Sector Portfolio

XMHQ

RPM Q3: Weather, Foreign Currency, and Lower Demand Weigh on Performance, Guidance Sees Modest Growth Ahead

<a href="https://www.finance.senate.gov/hearings/the-presidents-2025-trade-policy-agenda" title="https://www.finance.senate.gov/hearings/the-presidents-2025-trade-policy-agenda">https://www.finance.senate.gov/hearings/the-presidents-2025-trade-policy-agenda</a>

Macro Economic Events

Politics

Global

Economics

U.S. Trade Representative Jamieson Greer Says Reciprocal Tariffs Are Generally Lower In The Western Hemisphere

Truist Securities analyst Jamie Cook maintains United Rentals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/URI#NYSE">URI</a>) with a Buy and lowers the price target from $956 to $732.

Truist Securities Maintains Buy on United Rentals, Lowers Price Target to $732

Keybanc analyst John Vinh maintains ON Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) with a Overweight and lowers the price target from $60 to $55.

Keybanc Maintains Overweight on ON Semiconductor, Lowers Price Target to $55

Truist Securities analyst Jamie Cook maintains Cummins (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMI#NYSE">CMI</a>) with a Hold and lowers the price target from $420 to $338.

Truist Securities Maintains Hold on Cummins, Lowers Price Target to $338

U.S. Trade Representative Jamieson Greer Says Best Way To Have Pricing Certainty Is To Build Products In The U.S.

Truist Securities analyst Jamie Cook maintains PACCAR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCAR#NASDAQ">PCAR</a>) with a Hold and lowers the price target from $113 to $104.

PCAR

Truist Securities Maintains Hold on PACCAR, Lowers Price Target to $104

U.S. Trade Representative Jamieson Greer Says Price Challenge From Trump's Tariffs Will Affect Companies That Are Largely Dependent On Imports From China And Asia

Truist Securities analyst Jamie Cook maintains Caterpillar (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>) with a Buy and lowers the price target from $438 to $389.

Truist Securities Maintains Buy on Caterpillar, Lowers Price Target to $389

JP Morgan analyst Pablo Singzon maintains Goosehead Insurance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GSHD#NASDAQ">GSHD</a>) with a Neutral and raises the price target from $90 to $100.

GSHD

JP Morgan Maintains Neutral on Goosehead Insurance, Raises Price Target to $100

Truist Securities analyst Scot Ciccarelli maintains Target (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) with a Hold and lowers the price target from $124 to $82.

Truist Securities Maintains Hold on Target, Lowers Price Target to $82

JP Morgan analyst Pablo Singzon maintains Fidelis Insurance Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIHL#NYSE">FIHL</a>) with a Neutral and lowers the price target from $19 to $18.

FIHL

JP Morgan Maintains Neutral on Fidelis Insurance Hldgs, Lowers Price Target to $18

Press Releases

VS MEDIA Announces Fiscal Year 2023 Financial Results

VS Media Provides Recent Updates to Shareholders

VS Media Holdings Limited Announces 1-for-7 Share Combination

VS Media Holdings Limited Announces Delay in Effective Date of Reverse Split to June 18, 2024

VS Media Holdings Limited Regains Compliance with Nasdaq Minimum Closing Bid Price Requirement

5 Must-Watch Stocks Under $5: NIXX, PRSO, VSME, BREA, STAF

Peraso Inc. (NASDAQ: PRSO): Revolutionizing Military Combat with Steerable Beam Technology see more stocks inside…

VS Media Announces Strategic Acquisitions and Unveils Comprehensive Growth Strategies

VS Media Successfully Integrates Strategic Acquisitions, Driving Global Expansion and Profitability

BNZI

BREA

DRUG

ILLR

NIVF

NIXX

PRSO

RANI

STAF

TVGN

VMAR

VSME

XPON

Antelope Enterprise Holdings Limited - Class A Ordinary Shares

Antelope Ent Hldgs

Cheer Holding, Inc. - Class A Ordinary Share

Cheer Holding

Fangdd Network Group Ltd. - Class A Ordinary Shares

Fangdd Network Group

Phoenix New Media Limited American Depositary Shares, each representing 48 Class A ordinary shares.

Comments

VS Media Holdings

VS Media Holdings (VSME) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO